Abstract
Successful prophylaxis of ventricular arrhythmias in acute myocardial infarction might achieve a major reduction in mortality of this condition. No satisfactory drug is yet available, but many new antiarrhythmic agents are being tested in this role. Such placebo controlled investigations in the earliest phase of myocardial infarction encounter unique problems of study design, drug pharmacokinetics, study conduct, and data analysis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
